Targeted drugs and radiation for BRAF-mutated thyroid cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial studies whether targeted medicines (dabrafenib and trametinib) plus radiation can control an aggressive thyroid cancer with a specific BRAF gene change. It may help by attacking cancer cells that have this mutation and using focused radiation to improve tumor control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of anaplastic thyroid cancer from a tissue or fluid sample.
- Your tumor must test positive for a BRAF mutation called V600E or V600K.
- You are well enough for treatment (ECOG performance status under 2).
- Your blood counts and organ tests meet specific minimums (neutrophils, hemoglobin, platelets, liver enzymes, kidney function).
- If you can get pregnant, you must have a negative pregnancy test and use very reliable birth control during the study and for months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
This trial compares a targeted therapy pill combination (dabrafenib and trametinib) with cabozantinib or chemotherapy for people with a specific type of advanced thyroid cancer (differentiated thyroid cancer) that has a BRAF V600E mutation. It aims to find which treatment works better after previous treatments have stopped working.
This Phase 2 trial tests a targeted treatment for adults with papillary craniopharyngioma that has a specific BRAF change (V600E). It may help shrink or control the tumor, especially when surgery is not expected to remove it safely.
Hear when a new BRAF NP_004324.2:p.V600E trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.